Several colony stimulating factors (CSFs) and cytokines have been successfully used to mobilize hematopoietic cells during myeloablative therapy, bone marrow failure, and transplantation and to provide supportive treatment during sepsis. The use of yeastderived recombinant human granulocyte-macrophage CSF (rhuGM-CSF) and its interleukin-3 fusion protein, PIXY321, provides an example of issues associated with development programs for recombinant hematopoietic growth factors.
INTRODUCTION
Growth factors are molecules that transmit signals between cells, function as growth stimulators or inhibitors, and often modulate differentiation of stem cells. These factors are divided into superfamilies and families based on structural homologies and are divided functionally into factors with tissue-specific or broad activity. Hematopoietic growth factors include both colony-stimulating factors (CSFs) and cytokines involved in differentiation, maturation, and regulation of stem, progenitor, and committed hematopoietic cells. The capacity of bone marrow cells to form stem or lineage-specific colony-forming units in semisolid agar allows purification and cloning of CSFs that drive hematopoietic cell growth and lineage maturation (27, 28, 34, 51) .
Hematopoietic growth factors that affect myelopoiesis include granulocyte-macrophage CSF (GM-CSF), granulocyte CSF (G-CSF), macrophage CSF (M-CSF), and interleukin (IL)-3. GM-CSF influences proliferation and maturation of the myeloid stem cell, granulocyte and monocyte progenitors, and committed granulocytes and monocytes (Fig. 1 ). The biologic effects of GM-CSF produced by T lymphocytes, endothelial cells, fibroblasts, and macrophages result from binding to the receptor on myeloid cells (paracrine loop). GM-CSF receptor has a unique alpha chain but shares a common beta chain ((3c) with IL-3 and IL-5. Coexpression of receptors is frequent and results in similarity and overlapping functions as observed with GM-CSF, G-CSF, M-CSF, and IL-3 (10, 35, 40) .
Recombinant forms of CSFs have provided a new class of therapeutic biologicals (34) . Yeast-derived recombinant human (rhu) GM-CSF (rhuGM-CSF; sargramostim; Leukine@) and G-CSF were 2 of the earliest recombinant human CSFs expressed and shown to have clinical efficacy in cancer therapy. The therapeutic applications of rhuGM-CSF and rhuG-CSF overlap and focus on treatment of neutropenia to support patients with chemotherapy-and radiation-induced cytopenias, leukemias, mobilization of stem cells, acute infectious disease, and neonatal sepsis (8, 13, 25, 30, 34, 35) . Issues that arise in development of hematopoietic growth factors include species-specific binding and bioactivity, immunogenicity, appropriate mobilization of target cells, and relevance of reported adverse clinical responses. These issues are reviewed here using yeast-derived rhuGM-CSF and PIXY321, the GM-CSF/IL-3 fusion protein, as representatives of this class of biologicals.
GENERAL ISSUES IN DEVELOPMENT OF BIOLOGICALS
Development programs for biologicals are similar in many respects to those for traditional pharmaceuticals. Biologicals differ in that they are produced by recombinant DNA technologies, may have unique formulations (e.g., fusion molecules), are often proteins, and are often intended for clinical indications for which no therapies currently exist. Toxicity is often immunologically related because many biologicals replace or supplement endogenous immunoregulatory molecules or use novel therapeutic approaches that modulate the immune response (e.g., therapeutic antibodies). Consequently, preclinical and clinical development programs must be carefully planned to accommodate these differences. In particular, the inherent limitations of biologicals results in a science- based approach to the design of animal studies that may emphasis efficacy rather than toxicity in animal models of specific human diseases. Where immunogenicity or species specificity exists, preclinical toxicity data may be restricted to nonhuman primates and limited in duration (17, 29, 45) . A no-observable-adverse-effect level may be difficult to demonstrate in the presence of cascading pharmacologic effects such as those occurring with cytokine release syndromes during cytokine treatment (5) . Conversely, biologicals such as soluble cytokine receptors lack inherent biologic activity, and changes in normal tissues may be undetectable (45, 47) .
In clinical trials, successful new drugs should positively influence at least one of the 9 D's: death, disease, distress, disability, dysfunction, disposition, debt/dollars, drug effects (toxicity), and disharmony (31 ) . Hematopoietic growth factors may be positive by enhancing time to recovery from cytopenias and reducing infections and the need for hospitalization. However, poorly designed or controlled studies, emphasis on low-priority surrogate markers, differences in results by site, primary versus relapsing malignancy, lower efficacy in young and old cohorts, high cost of production and administration, and adverse reactions with lack of survival benefit all negatively affect overall clinical benefit. Clinical and economic effectiveness are not synonymous. Demonstration of pharmacoeconomic benefit is becoming an important outcome defining success in clinical trials and determining therapeutic use of recombinant hematopoietic growth factors (2, 41, 48) .
GM-CSF: PRECLINICAL AND CLINICAL DEVELOPMENT
In Vitro Studies GM-CSF is a regulator of intermediate hematopoiesis in myeloid stem cells, granulocyte, erythroid, myeloid, and megakaryocyte progenitors, and mature granulocytes and monocytes. Functional properties of myeloid cells are altered with GM-CSF in vitro. Neutrophils show enhanced survival, increased priming, phagocytosis, killing, adhesion, and migration but limited chemotaxis in response to GM-CSE Tumoricidal action, cytotoxicity, increased killing of Leishmania sp., upregulated tumor necrosis factor, and increased antigen presentation are responses of monocytes and dendritic cells to GM-CSF (16, 33, 35) . Binding studies show receptor densities of 500-800 sites/cell on mature granulocytes and 150 sites/cell on monocytes. There is a linear correlation between effectiveness and receptor saturation, and glycosylation is inversely related to binding affinity. Upon binding, ligand is internalized and downregulates the receptor (35, 49) .
Preclinical Studies
Species specificity of GM-CSF and immunogenicity of recombinant human proteins limits the usefulness of all but short-term preclinical studies in laboratory animals (45, 47) . rhuGM-CSF does not bind to mouse cells, recombinant murine GM-CSF does not bind to human cells, and there is no cross-reactivity between these GM-CSFs (26, 35) . Murine GM-CSF administered to mice does not produce the dose-dependent hematopoietic activity that rhuGM-CSF does in humans (22, 35) . Rapid splenic and hepatic extramedullary hematopoiesis, diffuse medullary distribution of active bone marrow in mice, and differences in receptor genes and glycosylation patterns in molecules may be partially responsible for the species specificity and pharmacokinetic patterns observed with CSFs in mice versus humans (34, 35, 40) . Generation of homologous molecules in selected test species may also not be feasible because of technical difficulties in cloning, expression, and purification and increased cost and time required to generate additional recombinant molecules. Although limited studies have been done with all CSFs, modification of molecules by water-soluble polymer protectants such as polyethylene glycol may result in increased bioactivity and may allow additional preclinical testing because of the increased bioavailability and reduced toxicity and immunogenicity (7, 47) . Contrived animal models, particularly transgenic mice or mice with engrafted recombinant hematopoietic cells, have been proposed for preclinical evaluation of biologicals (22, 46) . However, the relevance and validity of such models has not been adequately determined. Histopathologic evaluation of these models by toxicologic pathologists is also lacking. Genetically engineered models must be carefully interpreted in the context of genetic background and known background lesions, enhancement of opportunistic infections in immunologically altered mice, variability of vector expression among animals, type and location of insertional event, type of promoter, producion of abnormal autocrine loops, and other direct or indirect effects that may result in spurious or accidental pathologic changes and altered pharmacokinetics.
Preclinical studies in mice, dogs, and nonhuman primates show that daily or continuous infusion of GM-CSF results in a triphasic pattern that includes transient neutropenia (5-120 min) followed by neutrophilia (mobilized from storage pools) and an increase in circulating neutrophils at 72-96 hr after treatment (new neutrophil production). Absolute monocyte, eosinophil, and lymphocyte counts are increased. Platelet production is variable, and erythropoiesis has not been observed in animal studies (16, 35) . In acute and subacute toxicity studies in rodents and monkeys treated with rhuGM-CSF produced in yeast, mammalian (Chinese hamster ovary [CHO]) cells, and E. coli, pharmacologic effects manifest as mobilization of granulocytes, variable leukocytosis, splenic enlargement, bone marrow hyperplasia, and injection site reactions. High-dose adverse effects in monkeys consisting of facial erythema and edema, decreased motor activity, decreased body weight and death with polyserositis reported for CHO-and E. coli-derived rhuGM-CSF (35) were not found in studies with yeast-derived rhuGM-CSF (unpublished data).
CLINICAL STUDIES
Clinical trials for GM-CSF have focused on reducing treatmentor disease-related cytopenias in chemotherapy, bone marrow transplantation, and bone marrow. Efficacy has been demonstrated for bone marrow transplantation in Hodgkin's disease, lymphoid malignancies, ovarian cancer, sarcomas and myelodysplastic syndromes (2, 9, 15, 19, 23, 32, 41, 43, 44, 48, 49, 51, 53) . In low-birthweight infants, GM-CSF is also effective for preventing sepsis (38) . GM-CSF and G-CSF are useful for treating congenital and induced neutropenias and may be effective in treating myeloid leukemias, aplastic anemia, and AIDS (27) . Neutropenia associated with HIV infection in patients treated with myelosuppressive agents can also be corrected with GM-CSF or G-CSF (11) . In most studies, there were dose-related increases in neutrophils, reduced median duration of neutropenia, and reduced antibiotics and hospitalization requirements, and patients were able to tolerate and complete more cycles of chemotherapy.
However, in several studies cost effectiveness of treatment could not be demonstrated (2, 41, 48) . Promising effects of GM-CSF are being demonstrated for other clinical uses, including wound healing, skin engraftment, cytostatic/radiotherapy mucositis treatment, adjuvancy, antifungal therapy, and antiviral (e.g., HIV) therapy (24, 30, 35) .
Pharmacologic exaggeration and adverse reactions are found in many biologicals, including hematopoietic growth factors (50) . Both GM-CSF and G-CSF have shown adverse reactions that include low-grade constitutional signs (bone pain and cutaneous reactions), doselimiting cytokine release syndromes, and contraindications (Felty's syndrome and >20% blast cells) (27, 42) . Although GM-CSF has been reported to have broader and more severe adverse effects than G-CSF, rhuGM-CSF is well tolerated and the adverse reactions are similar to those found with rhuG-CSF (3, 30, 50) . Some adverse events due to administration of GM-CSF have only been reported in early clinical trials, and a reduction in adverse reactions has occurred with optimized doses and schedules (3, 30) . Fewer adverse reactions are reported with yeast-derived than with E. coli-derived rhuGM-CSE The vast majority of adverse reactions reported with yeastderived GM-CSF are flulike low-grade constitutional signs that can be managed with minimal supportive therapy (50) . Also, the impact of concurrent illness and treatments and of paraneoplastic syndromes on the extent and severity of adverse reactions in patients treated with GM-CSF has not been generally considered in retrospective studies. In the only clinical trial comparing GM-CSF and G-CSF, no difference was found in adverse reactions except for a minimal increase in body temperature with GM-CSF treatment (3).
Immunogenicity has been reported for several recombinant human growth factors, although immunosuppression in patients may alter the frequency, appearance of, and ability to detect antibodies. Regardless, production of antibodies during treatment often modifies pharmacoki-netics, interferes with induction of the intended therapeutic effect, and results in fewer adverse events. Similar to adverse reactions in general, immunogenicity reported for GM-CSF is more frequent (up to 95% of immunocompetent patients) with the E. coli-derived (36) than with the yeast-derived rhuGM-CSF (14, 39) . Lack of glycosylation sites in E. coli-derived rhuGM-CSF and hyperglycosylation and heterogeneity of glycosylation in yeastand CHO-derived rhuGM-CSF account for some of the differences in production of antibodies to these recombinant proteins (14, 35) .
DEVELOPMENT OF IL-3 IL-3, or multi-colony stimulating factor, is the broadest acting myelopoietic CSE IL-3 overlaps hematopoietic activity of GM-CSF but also directly enhances erythropoiesis and megakaryocytopoiesis. In general, IL-3 is not as well tolerated as GM-CSF or G-CSF, detracting from the potential therapeutic application of this molecule. Similar to other related hematopoietic growth factors, species specificity of IL-3 and immunogenicity of human proteins limited preclinical testing. Clinical trials with IL-3 have been directed towards support during myeloablative therapy, stem cell support (aplastic anemia and myelodysplastic syndromes), stem cell mobilization, and bone marrow transplantation. However, despite clinical efficacy, adverse effects included numerous and severe lowgrade reactions and dose-limiting reactions such as cytokine release syndromes, cutaneous necrosis, exacerbation of arthralgia, atrial fibrillation, and severe hypotension and nephropathy in conjunction with carboplatin. Combination therapy consisting of sequential administration of IL-3 and GM-CSF was better tolerated with fewer and less severe adverse reactions (27, 40, 50) .
To further explore potential therapeutic and economic benefits that might be derived from GM-CSF and IL-3 combination therapy (53) , a unique fusion protein was created. Because GM-CSF and IL-3 share a common receptor subunit, the PIXY321 fusion protein was developed with the intent of capitalizing on overlapping function of these molecules with the goal of reducing toxicity and accessing the unique role of IL-3 on platelet maturation.
GM-CSF AND IL-3 FUSION PROTEIN
Fusion or synthetic proteins provide a system for production of multivalent molecules and combinations of molecules with complementary and synergistic biologic activities (18, 34, 50) . For example, fusion of ligands or receptors with the Fc portion of human immunoglobulin results in bivalent forms with higher affinity and lower dissociation constants than those of monovalent derivatives (20) . The first human growth factor fusion protein, PIXY321, was created using a flexible amino acid linker sequence between the active domains of GM-CSF and IL-3 and was expressed in yeast (Saccharomyces cerevisiae). Fusion proteins may be heterogenous in glycosylation patterns; therefore, successful control of relative frequencies of heterogeneities was required to reproducibly provide a consistent product for clinical trials (1) .
In Vitro Studies PIXY321 stimulates progenitor and committed stem cells through erythropoiesis, myelopoiesis, and megakaryocytopoiesis (49, 50) . Similar to GM-CSF, IL-3, and G-CSF, PIXY321 is effective in ex vivo expansion of CD34progenitor cells (21, 55) and mobilizes more CD34+ cells than does GM-CSF (21) . In vitro studies indicate that PIXY321 binds to cells expressing receptors for either GM-CSF or IL-3 (49, 50) .
Preclinical Studies
Results of single-dose and multidose preclinical studies in nonhuman primates treated with PIXY321 were similar to those of animals treated with rhuGM-CSF alone, with pharmacologic changes consisting of peripheral and tissue leukocytosis with granulocytosis (49) . Rhesus monkeys exposed to 450 cGy total body irradiation were treated with GM-CSF, IL-3, and PIXY321 given as subcutaneous injections twice daily for 21 days. PIXY321 enhanced neutrophil recovery faster and reduced the number of days of leukopenia and antibiotic coverage more than did GM-CSF treatment. Additionally, PIXY321 and IL-3 enhanced platelet recovery and reduced the days of thrombocytopenia as compared with GM-CSF treatment (54) . Concomitant administration of GM-CSF and IL-3 is superior to sequential administration (49) .
Clinical Studies
Prechemotherapy patients treated with PIXY321 exhibited modest increases in leukocytes, platelets, reticulocytes, and bone marrow cellularity. In early clinical trials, PIXY321 induced rapid and sustained hematopoietic recovery in patients with lymphoma (4) . In a breast cancer trial, PIXY321 and GM-CSF were similar in producing a shorter time to hematologic recovery, but PIXY321 1 was thought to confer an advantage in platelet recovery (37) . PIXY321 also appeared to allow intensification of chemotherapy by suppression of progenitor cell cycling in bone marrow and peripheral circulation. Changes were related to dose and not to production of antibodies (6) . Overall, PIXY321 was generally well tolerated, with some injection site reactions, low-grade fever, chills, fatigue, headache, myalgia, and mild gastrointestinal symptoms (49) . In children undergoing myelosuppressive chemotherapy, PIXY321 was safe but had no clinical effects. Low plasma levels were associated with enhanced clearance over prolonged administration, and negative feedback from cells regulating hematopoiesis was thought to be involved (12) . Immunogenicity was not identified in patients treated with PIXY321 (49) . Mobilization of platelets was the major therapeutic advantage for PIXY321 over GM-CSF, and subsequent trials focused on platelet recovery.
In late clinical trials, PIXY321 improved neutrophil engraftment but not platelet mobilization compared with GM-CSF treatment in bone marrow transplantation for non-Hodgkin's lymphoma (52) . A comparison of GM-CSF and PIXY321 after multiple chemotherapeutic cycles in breast cancer patients indicated that PIXY321 was less well tolerated, and there was no difference in neu-trophil nadars or reduction in thrombocytopenia compared with GM-CSF treatment.
Therefore, despite previous demonstration of enhancement of in vitro and in vivo mobilization of platelets, PIXY321 was unable to provide large or consistent platelet mobilization in double-blind clinical trials and slightly increased some adverse reactions when compared with rhuGM-CSF treatment alone (32) . Reduced megakaryocytopoiesis associated with chemotherapy was often clinically insignificant because of the low platelet threshold required to prevent bleeding (52) . The cost of production of PIXY321 and lack of additional clinical or economic advantage over GM-CSF halted further development of this unique molecule. Figure I was produced by Gary Carlton. The editorial assistance of Anne Aumell is appreciated.
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